Dianthus Therapeutics (DNTH) Citigroup’s Biopharma Back to School Summit 2026 summary

Pipeline progress and clinical updates

• Claseprubart showed positive phase II results in myasthenia gravis and promising interim data in CIDP, with phase II MMN results expected in December and a phase III start planned soon after.

• Over-enrollment in the MMN phase II trial reflects strong community interest; primary focus is safety, with efficacy trends also monitored.

• DNTH212 is in phase I SAD in healthy volunteers, with an update and MAD study plans to be shared by year-end; DNTH312 is being prepared for phase I by end of next year.

• The CAPTIVATE phase III CIDP trial is progressing, with updates on patient numbers and top-line result timing expected before year-end.

• The EMERGE phase III MG study is underway, with top-line results anticipated in the second half of 2028.

Market positioning and competitive landscape

• Claseprubart is positioned as a best-in-class complement inhibitor for MG, with rapid onset, convenient dosing, and potential for first- and second-line use.

• The product aims to capture significant market share due to its safety, ease of use, and efficacy, especially among younger, active patients.

• In CIDP, the main opportunity is converting IVIG patients, as early data show many do better on claseprubart; entrenched IVIG use is a barrier, but better tolerability and self-administration are key advantages.

• Competitors in CIDP face challenges such as less potent inhibition, more frequent dosing, or safety disadvantages, potentially delaying their market entry.

• MMN development strategy will be informed by argenx's phase III results, with plans to replicate successful endpoints and leverage superior potency.

Early-stage pipeline and future outlook

• DNTH212 prioritizes SLE as the first indication, with updates on phase I progress and future study timelines expected by year-end.

• DNTH312, a dual C1s and BAFF/APRIL inhibitor, will leverage existing expertise and relationships, targeting neuromuscular indications and extending the franchise's patent life into the 2050s.

• The company holds $1.2 billion in cash, providing runway into 2030 and supporting execution across all programs and indications.

• Multiple catalysts are expected in the coming months, including clinical data readouts and competitor updates that could further de-risk and validate the pipeline.